Drug Discovery
ADMET Optimization
Generate molecular modifications that optimize absorption, distribution, metabolism, excretion, and toxicity profiles while preserving target activity.
The Challenge
Why ADMET Optimization needs a new approach to generation
ADMET properties are the primary cause of drug candidate attrition — over 50% of clinical failures stem from pharmacokinetic or toxicity issues that were not adequately addressed during lead optimization. The challenge is generative: given a molecule with demonstrated target activity, produce modified analogs that improve metabolic stability, oral bioavailability, clearance profile, and safety margins without losing the binding characteristics that make the molecule therapeutically useful. This multi-objective molecular modification problem is poorly served by current tools.
Existing ADMET optimization workflows rely on medicinal chemists iterating through structural modifications guided by empirical rules — blocking metabolic soft spots, modulating lipophilicity, adding solubilizing groups — in sequential design-make-test cycles. Each modification risks disrupting the carefully optimized binding interactions. Computational ADMET prediction models can score proposed modifications but cannot generate the modifications themselves, leaving the creative design step entirely to human intuition.
The MatterSpace Approach
How MatterSpace generates for admet optimization
MatterSpace Pharma generates ADMET-optimized molecular variants by treating the modification as a constrained generation problem: maintain the pharmacophore and binding mode while exploring chemical modifications that shift ADMET properties into the desired window. The system generates modifications that are synthetically accessible and preserve the structural features responsible for target engagement.
The ADMET domain pack encodes metabolic pathway prediction, transporter interaction models, CYP inhibition risks, and toxicophore databases. Users define the parent molecule, binding mode constraints, and target ADMET property windows. Pharma generates modified analogs with predicted property profiles, highlighting trade-offs and Pareto-optimal candidates.
Constraint-Based Generation
Specify what the output must satisfy. MatterSpace constructs candidates that meet all constraints simultaneously.
Valid by Construction
Every output satisfies physical laws, stability criteria, and domain constraints — no post-hoc filtering needed.
MatterSpace Pharma
Powered by a domain-specific generation engine with physics-aware priors and adaptive dynamics control.
Generation Output
What MatterSpace generates
- Metabolically stabilized analogs with preserved binding modes
- Bioavailability-optimized molecular variants
- Toxicity-mitigated candidates with safety margin predictions
- CYP interaction profiles for generated modifications
Key Differentiators
Why MatterSpace is different
MatterSpace Pharma generates ADMET-optimized analogs that preserve target binding by construction, resolving the potency-properties trade-off that dominates medicinal chemistry. The system proposes modifications beyond common medicinal chemistry heuristics, accessing chemical solutions in molecular space that iterative manual optimization would take months to explore.
Same sector
Related industries
Small Molecule Drug Design
Generate novel small molecule candidates optimized for target binding affinity, selectivity, and drug-likeness from a therapeutic specification.
ViewBiologics and Antibody Engineering
Generate novel antibody sequences and biologics candidates with predicted binding specificity, developability, and immunogenicity profiles.
ViewPeptide and Macrocycle Design
Generate novel peptide sequences and macrocyclic structures with target binding affinity, proteolytic stability, and cell permeability for challenging therapeutic targets.
ViewGet started
Start generating with MatterSpace
Whether you are exploring admet optimization for the first time or scaling an existing research programme, MatterSpace generates novel candidates that satisfy your constraints by construction.
Contact us